Severe Flu Season Provides an Opportunity for Molecular POC

It’s late January, 2018. It’s the centenary of the opening salvos of the “Spanish” Flu Pandemic, the unsung (and misnomered) villain of the later days of The Great War.  With cases on the rise right now, the 2017-’18 flu season has yet to reach its peak[1], surpassing that of the 2012-’13 season, and young people […]

Top 10 Companies in Liquid Biopsy Detailed in New Report

 New York City-based healthcare market researcher Kalorama Information details the top 10 liquid biopsy companies and their activities in a new report.  The market, Kalorama says, is heterogeneous and very fragmented, with many companies commercializing various liquid biopsy diagnostic products and developing new ones for a broad range of applications.  But a few top competitors […]

Promise of Fast Growth Propels Molecular Technologies in Fighting Infections

Make sure to visit our In Vitro Diagnostics page, Kalorama’s all-in-one resource covering the IVD market.  Infectious Disease Molecular IVD Market: Fastest Growth of Any Molecular Test Segment Infectious Disease is the best-selling and fastest-growing part of molecular testing, as Kalorama notes in its report Infectious Disease Diagnostics.     Molecular diagnostics’ performance and applicability is unparalleled among IVD […]

Qiagen Adds to Leading Molecular Cancer Menu with FDA-Cleared JAK2 Test Kit

Prognostic and Other Evaluative Tests Kits Join Companion Diagnostics in U.S. Cancer Diagnostics.  Kalorama Information covers molecular in vitro diagnostics (IVD) markets for cancer and blood disorders inThe World Molecular Diagnostics Market, 7th Ed. The U.S. Food and Drug Administration (FDA) recently cleared Qiagen’s ipsogen JAK2 RGQ PCR Kit for detection of the V617F mutation on […]

Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World

Multiplex Immunoassays Could Develop as a Cheaper Panel Testing Option for Tropical Diseases Kalorama Information reports cover the related global markets for point of care (POC) diagnostics and molecular POC diagnostics. Make sure to visit our Point of Care Testing page, Kalorama’s all-in-one resource covering the POC testing market.  The sensitivity and specificity of nucleic acid analytes provide molecular […]

Recent Autism Test Studies Add to Promising, Yet Inconclusive Research into Psychiatric Diagnostics

Kalorama Information covers in vitro diagnostics (IVD) markets for autism spectrum disorders (ASDs) and other psychiatric disorders in The World Molecular Diagnostics Market, 7thEd.  and Novel Autism Diagnostics. In two recent studies, in vitro diagnostic (IVD) assays have been investigated that incorporate biomarkers for environmental factors and dysfunctional cellular pathways associated with autism spectrum disorders (ASDs). The accuracy […]

Drive for Prevention to Fuel Food Safety Diagnostics

This article is based on information in Kalorama Information’s Food Safety Diagnostics Market Report (https://www. Safety-Diagnostics-12090767/ ).   Food safety concerns are increasing globally as international food trading is growing at a fast pace. Industrialization of food consumption is another major trend in many countries including several emerging markets, which in turn is pushing the growth of international […]

Recent Companion Dx Deals

Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the […]

IVD in 2019: Eight Out-of-the-Box Predictions

Kalorama Information is the Publisher of The Worldwide Market for In Vitro Diagnostics, 11th Edition, the definitive report on the IVD market.  Based on our 2018 research, here are 8 little-discussed trends that we expect to unfold in 2019: 1 Another Year of “Prove to Play” for Tests– Yes, your new 2019 diagnostic test product will be […]